Methafly F Tablet contains a synergistic combination of Furazolidone 100 mg and Metronidazole 300 mg, formulated to deliver broad-spectrum antimicrobial and antiprotozoal action. This combination works by inhibiting microbial enzyme systems and disrupting DNA synthesis, effectively controlling intestinal pathogens responsible for gastrointestinal infections.
This tablet is commonly prescribed for acute infectious diarrhea, amoebiasis, giardiasis, bacterial dysentery, and mixed intestinal infections. Furazolidone provides strong antibacterial coverage, while Metronidazole targets anaerobic bacteria and protozoa, making the combination highly effective in conditions where single-drug therapy may be insufficient.
The oral tablet formulation ensures rapid absorption, consistent therapeutic levels, and improved patient compliance. It is suitable for use in hospitals, clinics, nursing homes, and retail pharmacies, making it a reliable choice for physicians managing infectious gastrointestinal disorders in both adults and adolescents.
Methafly F Tablet helps in rapid symptom relief, reduction of infection severity, prevention of dehydration complications, and faster recovery of gut health. Its well-balanced composition, proven efficacy, and favorable safety profile make it a preferred option in the gastrointestinal anti-infective therapy segment for routine and severe infection management.